Targeted group by risk factor and current age | Primary dose(s) of MenACWY | Future booster dose(s) of MenACWY if increased risk persists |
Children with anatomic or functional asplenia* (including sickle cell disease) or HIV infection | ||
Age 2 through 6 months | Initiate series with MenACWY-CRM as soon as possible:
|
|
Age 7 through 23 months | 2 doses of MenACWY-CRM¶, ≥12 weeks apart | |
Children with complement component deficiency* (eg, C3, C5-C9, properdin, factor H, factor D) or using complement inhibitors (eg, eculizumab, ravulizumab)* | ||
Age 2 through 6 months | Initiate series with MenACWY-CRM as soon as possible:
|
|
Age 7 through 23 months | 2 doses of MenACWY-CRM¶, ≥12 weeks apart | |
Children who travel to or are residents of countries where meningococcal disease is hyperendemic or epidemicΔ | ||
Age 2 through 6 months | Initiate series with MenACWY-CRM as soon as possible:
| Not applicable |
Age 7 through 23 months | 2 doses of MenACWY-CRM¶, 12 weeks apart◊ |
MenACWY: meningococcal groups A, C, W, and Y conjugate vaccine; MenACWY-CRM (Menveo); CDC: United States Centers for Disease Control and Prevention.
* Children with these conditions should also receive serogroup B meningococcal vaccine at age ≥10 years.
¶ For children age 7 through 23 months, the second dose of MenACWY-CRM should be given at age ≥12 months.
Δ Vaccination is recommended for international travelers visiting the parts of sub-Saharan Africa known as the meningitis belt during the dry season (December to June). The CDC issues advisories for other countries during epidemics of vaccine-preventable serogroups. Additional traveler's health information is available from the CDC.
◊ The interval may be shortened to ≥2 months if the travel is scheduled in <3 months.آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟